Hutchmed sees its shares fall 15% after drug fails to receive US approval
Commercial stage biopharmaceutical company Hutchmed (HCM:AIM) said its pancreatic tumor drug surufatinib had failed to be approved by the US FDA (Food & Drug Administration), sending the shares 15% lower to 208p on Tuesday.The FDA...
03 May 2022